Literature DB >> 22094102

Protection against TNFα-dependent liver toxicity by intraperitoneal liposome delivered DsiRNA targeting TNFα in vivo.

Patric Lundberg1, Hui-Jung Yang, Seung-Jae Jung, Mark A Behlke, Scott D Rose, Edouard M Cantin.   

Abstract

Tumor necrosis factor-alpha (TNFα) is a classic proinflammatory cytokine implicated in the pathogenesis of several autoimmune and inflammatory diseases including viral encephalitis. Macrophages being major producers of TNFα are thus attractive targets for in vivo RNA interference (RNAi) mediated down regulation of TNFα. The application of RNAi technology to in vivo models however presents obstacles, including rapid degradation of RNA duplexes in plasma, insufficient delivery to the target cell population and toxicity associated with intravenous administration of synthetic RNAs and carrier compounds. We exploited the phagocytic ability of macrophages for delivery of Dicer-substrate small interfering RNAs (DsiRNAs) targeting TNFα (DsiTNFα) by intraperitoneal administration of lipid-DsiRNA complexes that were efficiently taken up by peritoneal macrophages and other phagocytic cells. We report that DsiTNFα-lipid complexes delivered intraperitoneally altered the disease outcome in an acute sepsis model. Down-regulation of TNFα in peritoneal CD11b+ monocytes reduced liver damage in C57BL/6 mice and significantly delayed acute mortality in mice treated with low dose LPS plus d-galactosamine (D-GalN).
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22094102      PMCID: PMC3321390          DOI: 10.1016/j.jconrel.2011.10.034

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  29 in total

Review 1.  Polycation-based nanoparticle delivery for improved RNA interference therapeutics.

Authors:  Kenneth A Howard; Jørgen Kjems
Journal:  Expert Opin Biol Ther       Date:  2007-12       Impact factor: 4.388

Review 2.  Delivery vehicles for small interfering RNA in vivo.

Authors:  Antonin R de Fougerolles
Journal:  Hum Gene Ther       Date:  2008-02       Impact factor: 5.695

Review 3.  Chemical modification of siRNAs for in vivo use.

Authors:  Mark A Behlke
Journal:  Oligonucleotides       Date:  2008-12

4.  Lipopolysaccharide and D-galactosamine-induced hepatic injury is mediated by TNF-alpha and not by Fas ligand.

Authors:  M D Josephs; F R Bahjat; K Fukuzuka; R Ksontini; C C Solorzano; C K Edwards; C L Tannahill; S L MacKay; E M Copeland; L L Moldawer
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2000-05       Impact factor: 3.619

5.  RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system.

Authors:  Kenneth A Howard; Ulrik L Rahbek; Xiudong Liu; Christian K Damgaard; Sys Zoffmann Glud; Morten Ø Andersen; Mads B Hovgaard; Alexander Schmitz; Jens R Nyengaard; Flemming Besenbacher; Jørgen Kjems
Journal:  Mol Ther       Date:  2006-07-10       Impact factor: 11.454

6.  Intraperitoneal administration of chitosan/DsiRNA nanoparticles targeting TNFα prevents radiation-induced fibrosis.

Authors:  Isabel Nawroth; Jan Alsner; Mark A Behlke; Flemming Besenbacher; Jens Overgaard; Kenneth A Howard; Jørgen Kjems
Journal:  Radiother Oncol       Date:  2010-10       Impact factor: 6.280

Review 7.  Drug delivery systems for intraperitoneal therapy.

Authors:  Gaurav Bajaj; Yoon Yeo
Journal:  Pharm Res       Date:  2010-03-03       Impact factor: 4.200

Review 8.  RNA interference in cancer.

Authors:  Andrei L Gartel; Eugene S Kandel
Journal:  Biomol Eng       Date:  2006-02-08

9.  A status report on RNAi therapeutics.

Authors:  Akshay K Vaishnaw; Jared Gollob; Christina Gamba-Vitalo; Renta Hutabarat; Dinah Sah; Rachel Meyers; Tony de Fougerolles; John Maraganore
Journal:  Silence       Date:  2010-07-08

Review 10.  Harnessing in vivo siRNA delivery for drug discovery and therapeutic development.

Authors:  Frank Y Xie; Martin C Woodle; Patrick Y Lu
Journal:  Drug Discov Today       Date:  2006-01       Impact factor: 7.851

View more
  11 in total

Review 1.  RNA interference trigger variants: getting the most out of RNA for RNA interference-based therapeutics.

Authors:  Nicholas M Snead; John J Rossi
Journal:  Nucleic Acid Ther       Date:  2012-06       Impact factor: 5.486

2.  Nonviral delivery of small interfering RNA into pancreas-associated immune cells prevents autoimmune diabetes.

Authors:  Wilhem Leconet; Pierre Petit; Sylvie Peraldi-Roux; Damien Bresson
Journal:  Mol Ther       Date:  2012-09-18       Impact factor: 11.454

3.  Supramolecular self-assembled nanoparticles mediate oral delivery of therapeutic TNF-α siRNA against systemic inflammation.

Authors:  Lichen Yin; Ziyuan Song; Qiuhao Qu; Kyung Hoon Kim; Nan Zheng; Catherine Yao; Isthier Chaudhury; Haoyu Tang; Nathan P Gabrielson; Fatih M Uckun; Jianjun Cheng
Journal:  Angew Chem Int Ed Engl       Date:  2013-04-22       Impact factor: 15.336

4.  Molecular basis for improved gene silencing by Dicer substrate interfering RNA compared with other siRNA variants.

Authors:  Nicholas M Snead; Xiwei Wu; Arthur Li; Qi Cui; Kumi Sakurai; John C Burnett; John J Rossi
Journal:  Nucleic Acids Res       Date:  2013-04-24       Impact factor: 16.971

5.  Functional inhibition of chemokine receptor CCR2 by dicer-substrate-siRNA prevents pain development.

Authors:  Valérie Bégin-Lavallée; Élora Midavaine; Marc-André Dansereau; Pascal Tétreault; Jean-Michel Longpré; Ashley M Jacobi; Scott D Rose; Mark A Behlke; Nicolas Beaudet; Philippe Sarret
Journal:  Mol Pain       Date:  2016-06-15       Impact factor: 3.395

Review 6.  Design, mechanism, delivery and therapeutics of canonical and Dicer-substrate siRNA.

Authors:  Maria Abdul Ghafoor Raja; Haliza Katas; Muhammad Wahab Amjad
Journal:  Asian J Pharm Sci       Date:  2019-02-13       Impact factor: 6.598

7.  Tumor necrosis factor-α small interfering RNA alveolar epithelial cell-targeting nanoparticles reduce lung injury in C57BL/6J mice with sepsis.

Authors:  Like Qian; Xi Yin; Jiahao Ji; Zhengli Chen; He Fang; Hu Li; Feng Zhu; Fei Chang
Journal:  J Int Med Res       Date:  2021-01       Impact factor: 1.671

8.  A novel recombinant slow-release TNF α-derived peptide effectively inhibits tumor growth and angiogensis.

Authors:  Yi Ma; Shaojun Zhao; Shutao Shen; Shixiong Fang; Zulu Ye; Zhi Shi; An Hong
Journal:  Sci Rep       Date:  2015-09-04       Impact factor: 4.379

9.  Identification of four novel serum protein biomarkers in sepsis patients encoded by target genes of sepsis-related miRNAs.

Authors:  Hui-juan Wang; Bao-zeng Wang; Peng-jun Zhang; Jie Deng; Zhi-rui Zhao; Xin Zhang; Kun Xiao; Dan Feng; Yan-hong Jia; You-ning Liu; Li-xin Xie
Journal:  Clin Sci (Lond)       Date:  2014-06       Impact factor: 6.124

10.  An Interferon Regulated MicroRNA Provides Broad Cell-Intrinsic Antiviral Immunity through Multihit Host-Directed Targeting of the Sterol Pathway.

Authors:  Kevin A Robertson; Wei Yuan Hsieh; Thorsten Forster; Mathieu Blanc; Hongjin Lu; Peter J Crick; Eylan Yutuc; Steven Watterson; Kimberly Martin; Samantha J Griffiths; Anton J Enright; Mami Yamamoto; Madapura M Pradeepa; Kimberly A Lennox; Mark A Behlke; Simon Talbot; Jürgen Haas; Lars Dölken; William J Griffiths; Yuqin Wang; Ana Angulo; Peter Ghazal
Journal:  PLoS Biol       Date:  2016-03-03       Impact factor: 8.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.